OncoMatch/Clinical Trials/NCT05926492
A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
Is NCT05926492 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Surufatinib plus chemotherapy and Chemotherapy for osteosarcoma.
Treatment: Surufatinib plus chemotherapy · Chemotherapy — This phase II study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Patients who have previously received chemotherapy drugs
Cannot have received: antiangiogenic agent (surufatinib)
Patients who have previously received...surufatinib, or other antiangiogenic agents
Cannot have received: systematic anti-tumor therapy
Received approved or under development systematic anti-tumor therapy within 4 weeks before enrollment, including chemotherapy, radical radiotherapy, biological immunotherapy, targeted therapy, etc.
Lab requirements
Blood counts
Neutrophil absolute value ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin concentration ≥9g/dL
Kidney function
serum creatinine ≤1.5×ULN, creatinine clearance (CCr)≥60ml/min
Liver function
aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, total bilirubin ≤1.5×ULN; In case of liver metastasis, AST and ALT≤5×ULN
Cardiac function
LVEF (Left ventricular Ejection Fraction) < 50% [excluded]; NYHA > level 2 [excluded]; acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; ventricular arrhythmias requiring medical treatment
Blood test (without blood transfusion within 14 days) 1) Neutrophil absolute value ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin concentration ≥9g/dL); 2) Liver function test (aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, total bilirubin ≤1.5×ULN; In case of liver metastasis, AST and ALT≤5×ULN); 3) Renal function (serum creatinine ≤1.5×ULN, creatinine clearance (CCr)≥60ml/min); LVEF (Left ventricular Ejection Fraction) < 50% [excluded]; NYHA > level 2 [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify